Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00587301
Other study ID # 11876
Secondary ID G050010
Status Completed
Phase N/A
First received
Last updated
Start date June 2005
Est. completion date July 8, 2020

Study information

Verified date March 2022
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to demonstrate the safety and efficacy of the use of the LAP-BAND surgery in the morbidly obese adolescent population.


Description:

STUDY OBJECTIVES: Is to demonstrate the safety and efficacy of the use of the LAP-BAND® System in the morbidly obese adolescent population in the United States, and therefore provide these individuals with a significantly less morbid and reversible surgical option for weight loss. STUDY VARIABLES:The primary efficacy variable is weight loss evaluated in terms of % excess weight loss (EWL). DESIGN:Prospective, open-label, and single center


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date July 8, 2020
Est. primary completion date July 8, 2020
Accepts healthy volunteers No
Gender All
Age group 14 Years to 17 Years
Eligibility Inclusion Criteria: - Be at least 14 and less than 18 years of age at the time of enrollment into the study. - Have a BMI of at least 40 - Have a history of obesity for at least 5 years, including failed attempts at diet and medical management of obesity. - Confirmation by a psychologist or psychiatrist experienced with adolescents that the subject is sufficiently mature emotionally to comply with the study protocol. Express willingness to follow protocol requirements. •Assure investigators that subject, if female of childbearing potential, is using an appropriate form of contraception. Exclusion Criteria: - Intention or need to have another surgical procedure for weight reduction within 12 months of Lap Band placement. - History of congenital or acquired anomalies of the G.I. tract, such as; congenital or acquired intestinal telangiectasia, Crohn's disease or ulcerative colitis; severe cardiopulmonary disease or severe coagulopathy; hepatic insufficiency or cirrhosis. - Presence of dysphagia or documented esophageal dysmotility. - Patients with autoimmune connective tissue disorders - Patients with acute abdominal infections - Pregnancy or intention of becoming pregnant in the next 12 months. - Presence of psychiatric problems or immaturity which would compromise cooperation with the study protocol. - History of previous bariatric surgery, intestinal obstruction or adhesive peritonitis. - Presence of localized or systemic infection at the time of surgery. - Chronic use of aspirin and/or non-steroidal anti-inflammatory medications and unwillingness to discontinue the use of these concomitant medications. - History of gastric or esophageal surgery. - Use of weigh loss medications simultaneously

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Lap-Band
Obesity and adolescents

Locations

Country Name City State
United States New York University School of Medicine New York New York

Sponsors (2)

Lead Sponsor Collaborator
NYU Langone Health Hope Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Excess Weight Loss (EWL) Year 1
Primary Percentage of Excess Weight Loss (EWL) Year 2
Primary Percentage of Excess Weight Loss (EWL) Year 3
Primary Percentage of Excess Weight Loss (EWL) Year 4
Primary Percentage of Excess Weight Loss (EWL) Year 5
Secondary Body Mass Index (BMI) Year 1
Secondary Body Mass Index (BMI) Year 2
Secondary Body Mass Index (BMI) Year 3
Secondary Body Mass Index (BMI) Year 4
Secondary Body Mass Index (BMI) Year 5
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2